Today, $Amgen (AMGN.US)$ announced the P2 trial results for ...

Today, $Amgen (AMGN.US)$ announced the P2 trial results for MariTide, which only include the safety profile for the 420 mg dose escalation cohorts (cherry-picking at it's finest again).

I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose escalations) exhibit the same disappointing GI safety profile as observed in Phase 1 (see slide 2).

The results today further solidify $Viking Therapeutics (VKTX.US)$ VK2735 QW and $Eli Lilly and Co (LLY.US)$ Retatrutide lead. I believe $NVO Cagrisema will also have great results in P3. The market so far seems to agree. $Viking Therapeutics (VKTX.US)$ VK 2735 is probably the best AOM out there.